Cart
This product is not clubbable with other items in cart. Please remove this or other items to proceed further.
Deleting

No Items In Cart
This product is not clubbable with other items in cart. Please remove this or other items to proceed further.
No Items In Cart
Enabling Large Volume (5-10mL) Injection in conjunction with a wearable device
The FluroTec® 5-10mL Cartridge Plunger is the perfect choice to help mitigate many of these risks. Reduce likelihood of drug adsorption and absorption, ensure you start the packaging process with low particulate components and crucially, knowing the plunger works in harmony with the other primary packaging components that make up your combination product.
FluroTec™ film is the premier choice to protect drugs from contamination by providing an effective barrier minimizing interaction between the drug and the closure while maintaining container closure integrity. Composed of ethylene tetrafluoroethylene (ETFE), FluroTec™ film also reduces absorption and adsorption of the drug product, an important benefit for maintaining the potency and shelf life of most drugs.
Assemble your container closure system by sourcing these Ready to Use components:
The Cartridge Plunger helps maintain container closure integrity, the system is free from leakage and delivers a consistent glide force for a smooth injection*.
You won’t be the first to choose a FluroTec™ component. Did you know there are over 130 approved drugs globally which utilize FluroTec™ as part of their packaging?
The FluroTec® 5-10mL Cartridge Plunger supports the growing need for large volume subcutaneous injection, which can enable the delivery of sensitive drugs in a home setting. Minimize likelihood of interactions with the same elastomer and FluroTec™ on both the plunger and stopper drug contact surfaces.
The Wearable devices market is young but has high potential. Wearable devices applications can be any of:
A consequence of the sustained shift of treatment from hospital to home is the evolution of on-body delivery systems (OBDS). OBDS platforms can deliver high volumes of medicines subcutaneously which traditionally would have been administered intravenously via an infusion at a clinic under the supervision of a healthcare professional (HCP).
Victoria Morgan
Director, Segment Marketing, Global Biologics
A consequence of the sustained shift of treatment from hospital to home is the evolution of on-body delivery systems (OBDS). OBDS platforms can deliver high volumes of medicines subcutaneously which traditionally would have been administered intravenously via an infusion at a clinic under the supervision of a healthcare professional (HCP).
Victoria Morgan
Director, Segment Marketing, Global Biologics